Trials / Not Yet Recruiting
Not Yet RecruitingNCT07110857
Evaluation of the Superficial Cervical Plexus Block in Oncological Throat and Neck Surgery
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 346 (estimated)
- Sponsor
- Assistance Publique - Hôpitaux de Paris · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
This national, prospective, multicenter, randomized study aims to reduce the amount of intravenous morphine (titration + PCA morphine) during the first 24 postoperative hours via a locoregional anesthesia technique in patients undergoing throat and neck cancer surgery.
Detailed description
The incidence of throat and neck (ENT) cancers is 15000 new cases/year in France. Nowadays, there are no studies with a sufficient level of evidence to establish formal recommendations on analgesic treatments to be applied in the context of ENT cancer surgery. As cancer surgery causes severe acute postoperative pain and chronic pain, loco-regional anesthesia (LRA) plays an increasingly role in the prevention of this type of pain. However, nowadays there is no data in the literature highlighting the interest of LRA in the context of ENT cancer surgery, despite a significant theoretical benefit. The superficial cervical block, already used in carotid or thyroid surgery, has already shown its value. It seems logical to propose this block in throat and neck cancer surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Cervical plexus block with 0.2 % Naropeine | Under ultrasound guidance, a superficial cervical plexus block is performed immediately after induction and before skin incision by injecting 15-25 mL of 0.2 % ropivacaine (Naropeine) uni- or bilateral depending on the surgical incision |
| PROCEDURE | Cervical plexus block with saline placebo | Under ultrasound guidance, a superficial cervical plexus block is performed immediately after induction and before skin incision by injecting 15-25 mL of 0.9 % saline uni- or bilateral depending on the surgical incision |
Timeline
- Start date
- 2025-09-01
- Primary completion
- 2027-06-01
- Completion
- 2027-09-01
- First posted
- 2025-08-08
- Last updated
- 2025-08-08
Locations
7 sites across 1 country: France
Source: ClinicalTrials.gov record NCT07110857. Inclusion in this directory is not an endorsement.